<DOC>
	<DOCNO>NCT00590915</DOCNO>
	<brief_summary>The purpose study make Erwinase available patient acute lymphoblastic leukemia ( ALL ) previous allergic reaction certain formulation L-asparaginase .</brief_summary>
	<brief_title>Erwinase Master Treatment Protocol</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Patient must give write informed consent receive Erwinase . Patient must treat acute lymphoblastic leukemia . Patient must either systemic hypersensitivity reaction native ( Elspar ) pegylated E.coli asparaginase ( Oncaspar ) . This include patient generalized rash without anaphylactic symptom , patient previously document local systemic reaction E.coli derive Lasparaginase . Previous allergic reaction Erwinia Lasparaginase ( Erwinase ) Previous acute pancreatitis Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ALL</keyword>
</DOC>